Radiopharm Theranostics Ltd has released a press release.
Radiopharm Theranostics: Half Yearly Report and Accounts
Filed with ASX ·
6ix hasn’t read this filing yet.
Radiopharm Theranostics Limited on 6ix
Earlier from Radiopharm Theranostics
- Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301
- Pilot Study Validates RAD Terbium-161 Radiotherapeutics
- Radiopharm receives $1.9 M advance on FY24 R&D tax incentive
- RAD secures Share Facility Agreement of up to A$12.5m
- RAD 502 can halt tumour progression and prolong survival
Later from Radiopharm Theranostics
- Radiopharm Receives Strategic Investment for up to A$18 mill
- Suspension from Quotation
- Radiopharm Theranostics completes A$70 million placement
- Reinstatement to Quotation
- First patient dosed in Phase 1 therapeutic lung cancer trial
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics